Bioresorbable polymers synthesized from monomer analogs of natural metabolites

Abstract

New bioresorbable polymers are synthesized from monomer analogs of natural metabolites In particular, polymers are polymerized from analogs of amino acids that contribute advantageous synthesis, processing and material properties to the polymers prepared therefrom, including particularly advantageous degradation profiles

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]The present application claims priority benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application Ser. No. 61 / 097,494 filed Sep. 16, 2008, the disclosure of which is incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]The present invention relates to new bioresorbable polymers synthesized from monomer analogs of natural metabolites. In particular, the present invention relates to polymers polymerized from analogs of amino acids that contribute advantageous synthesis, processing and material properties to the polymers prepared therefrom, including particularly advantageous degradation profiles.[0003]U.S. Pat. No. 5,099,060 discloses diphenolic monomers based on 3-(4-hydroxy-phenyl) propionic acid and L-tyrosine alkyl esters (desaminotyrosyl-tyrosine alkyl esters). Subsequent related patents involve variations of this basic monomer structure, including halogenated radiopaque diphenolic monomers, such as the 3,5-di-...

AI Technical Summary

Benefits of technology

[0078]By varying the molar fraction of poly(alkylene oxide) segments in the block copolymers provided by the present invention, the hydrophilic/hydrophobic ratios of the polymers can be attenuated to adjust the ability of the polymer coatings to modify cellular behavior. Increasing levels of poly(alkylene oxide) inhibit cellular attachment, migration and proliferation, whi

Problems solved by technology

These monomers, although useful in many applications, have several limitations:

Use of monomers having two phenolic hydroxyl groups, as disclosed in the above mentioned patent applications, tend to limit the resulting homopolymers to fully aromatic backbone structures.

Such polymers have generally good mechanical properties—but slow degradation rates.

Hence, such polymers will tend to have some use limitations as medical implant materials when the processes of degradation and resorption need to occur concomitantly.

As a result, implantable medical devices and drug delivery implants prepared from the previously described homopolymers that are intended to be resorbed are still substantially undissolved at the end of their useful life as measured by reduction in polymer molecular weight or mechanical strength.

This is particularly a problem for drug delivery implants and implantable medical devices that are intended to be replaced as part of a long-term treatment regimen.

However, implants formed with many of th

Images